InvestorsHub Logo
Followers 30
Posts 4193
Boards Moderated 0
Alias Born 07/25/2007

Re: DewDiligence post# 2087

Thursday, 11/18/2021 8:10:37 PM

Thursday, November 18, 2021 8:10:37 PM

Post# of 3059

The hit to the share price ought to be pretty modest inasmuch as EDP-721 was only in phase-1.



That is what I was guessing but who knows.


The question, of course, is whether the safety problem seen with EDP-721 is compound-specific or class-specific.



I assume the FDA will be extremely cautious with any RNA destabilizer of this class. I sure hope ENTA has other HepB targets in mind. Do you think ENTA will advance EDP-514 in trials in combination with a nuc, at least for now?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News